Physician profile
Kurt Bennett
NPI 1851720429
$9,637.42
in general payments reported to CMS, 2019-2025
18 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $88.53 · 2021: $515 · 2022: $1,452 · 2023: $1,093 · 2024: $5,062 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,401 · Travel and Lodging: $1,756 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,375 · Consulting Fee: $750 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,400.84 |
| Travel and Lodging | $1,755.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,375.00 |
| Consulting Fee | $750.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,336.84 | 2020-2025 | Total30, Dailies Total1, Precision 1 |
| Biotissue Holdings INC. | $1,574.98 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $1,159.78 | 2022-2025 | Miebo, Infuse, Xiidra |
| Johnson & Johnson Vision Care, INC. | $931.79 | 2021-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $333.79 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $207.22 | 2019-2021 | |
| Harrow Eye, LLC | $206.14 | 2024-2025 | Vevye |
| Coopervision INC. | $163.20 | 2020-2023 | Myday Contact Lens, Misight Contact Lens |
| Oyster Point Pharma, INC. | $124.91 | 2022-2025 | Tyrvaya, Ryzumvi |
| Regeneron Healthcare Solutions, INC. | $120.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $119.05 | 2021 | |
| Allergan, INC. | $96.76 | 2019 | |
| Heru, INC. | $72.38 | 2022 | |
| Glaukos Corporation | $50.78 | 2025 | Photrexa Viscous and Photrexa |
| Plexus Optix, INC. | $39.73 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $36.94 | 2024-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $35.05 | 2023-2025 | Cequa |
| Dompe US, INC. | $28.06 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.